🟢 Tvardi Therapeutics is trading 5.9% up today after Chardan's Buy initiation and $8.00 target

Tvardi Therapeutics is trading at $1.05, up 5.85%, after Chardan initiated coverage with a Buy rating and an $8.00 price target.

• Chardan initiated coverage on October 20; the recommendation is conditional on raising $35–$40 million to fund an ulcerative-colitis trial.
• Tvardi also presented at Chardan’s healthcare conference that day. Biotech strength provided sector context, but the analyst initiation was the clearer explanation for the premarket move.